FDA on Novartis data manipulation controversy: ‘We happened to be lucky’
DOMINICK REUTER/AFP/GETTY IMAGES
A top agency official suggested that the FDA was so distressed by the matter in part because the stakes in gene therapy research are so high.
Clinical and Molecular Allergy
Hace 19 horas
No hay comentarios:
Publicar un comentario